Resource Center
A Helpful Suite of Clinical Resources for Your Practice
Want to learn more about best practices in diagnosis and management of irritable bowel syndrome with diarrhea (IBS-D)? Access peer-guided videos, clinical tools, and comprehensive guides to help your patients throughout their journey.
PEER PERSPECTIVES
In this video series, Kathryn Jack, APRN, is “on call” to share her practical perspectives on common questions APPs have about identifying and caring for patients with IBS-D.
Video
3 mins
Episode 1: Addressing the Stigma of Symptoms
Patients are often reluctant to discuss gastrointestinal symptoms with their clinicians. Hear Kathryn’s approach to encouraging an open dialogue with patients and how she helps reduce the stigma associated with IBS-D symptoms.
Diagnosis of IBS-D
Video
11 mins
My Approach: Making a Positive IBS-D Diagnosis
A Practical Overview Featuring Jaime Ackerman, PA-C
Watch your peer demonstrate how she uses a guideline-based approach and clinical criteria to make a positive diagnosis of IBS-D.
Informational guide for diagnosing IBS-D, including clinical criteria and suggestions for conversation starters you can use with your patients.
Ten years since its last revision, Rome V provides updated clinical guidance and diagnostic criteria for IBS—see what’s changed and learn how you can incorporate a positive, symptom-based diagnostic approach into your practice.
Understanding IBS-D
Video
19 mins
Potential Causes of Your Adult Patients’ IBS-D Symptoms
Hosted by Christina J. Hanson, FNP
Featuring Amy Kassebaum, PA-C, MMS, RD
Learn about factors that are thought to contribute to IBS-D symptoms.
Video
3 mins
Bacterial Imbalance and IBS-D Symptoms
Video
6 mins
How XIFAXAN® (rifaximin) Is Thought to Work
Video
3 mins
Expert Discussion: The Role of Dysbiosis in the Pathophysiology of IBS-D
Watch Christopher Chang, MD, explain how microbial imbalances in the gut are thought to be linked to IBS-D symptoms.
Video
13 mins
Expert Discussion: Role Gut Microbiota May Play in the Etiology of IBS-D
Discussion from experts Mark Pimentel, MD, and Darren Brenner, MD, on the role of gut microbiota in human health and how dysbiosis may lead to symptoms of IBS-D.
Video
6 mins
Expert Discussion: Pathophysiology of IBS-D and Mechanism of Action of XIFAXAN
Discussion from expert Mark Pimentel, MD, on the complex pathophysiology of IBS-D and the mechanism of action of XIFAXAN.
PEER PERSPECTIVES
In this video series, Kathryn Jack, APRN, is “on call” to share her practical perspectives on common questions APPs have about identifying and caring for patients with IBS-D.
Video
3 mins
Episode 2: Efficient Care Delivery
Patients with IBS-D often delay seeking professional care and may learn to live with their symptoms. See Kathryn’s approach to making a prompt diagnosis and expediting management to meet her patients’ treatment goals.
Video
3 mins
Episode 3: Guideline-Directed Care
Management of IBS-D warrants careful consideration to accommodate patient preferences and help address multiple symptoms. Learn how Kathryn determines the best treatment pathway for her patients among the various management options available for IBS-D.
Clinical Practice
Watch fellow clinicians discuss clinical insights in the management of adult patients with IBS-D.
Video
10 mins
My Approach: Expediting IBS-D Management
A Practical Overview Featuring Tedra Gray, NP
See how your peer creates an open dialogue with a hypothetical patient, and gain insights into managing multiple symptoms of IBS-D. Discover why Tedra chooses XIFAXAN for her adult patients with IBS-D.
Video
16 mins
Expert Discussion: Treating IBS-D as a Multi-Symptom Condition
Watch Darren Brenner, MD, explain the importance of recognizing the multiple symptoms of IBS-D and how XIFAXAN may help address these symptoms.
Video
10 mins
Expert Discussion: Managing IBS-D Symptoms
Featuring Mark Pimentel, MD, Darren Brenner, MD, and Joscelyn Greaves, NP
Learn about nonpharmacologic and pharmacologic interventions to help manage IBS-D and the challenges faced by patients living with IBS-D.
Video
23 mins
Managing Your Adult Patients’ IBS-D Symptoms
Hosted by Christina J. Hanson, FNP
Featuring Kim Orleck, PA-C
Recognize the recurring symptoms of IBS-D, and learn how treatment with XIFAXAN may help provide relief for your appropriate patients.1,2
Video
3 mins
Connecting With IBS-D Patients and Defining Success
Video
8 mins
Managing IBS-D With XIFAXAN® (rifaximin)
EXPERT INSIGHTS
Video
7 mins
Expert Review: Efficacy and Safety of XIFAXAN
Darren Brenner, MD speaks about the efficacy and safety of XIFAXAN shown in clinical trials. Review key data supporting the use of XIFAXAN for your adult patients with IBS-D.
Video
4 mins
Expert Discussion: ACG Recommendation for XIFAXAN
Watch Brooks Cash, MD, discuss the inclusion of XIFAXAN as a treatment for adults with IBS-D in the American College of Gastroenterology’s 2020 Clinical Guideline on Managing IBS-D.
Video
16 mins
Expert Discussion: Treating IBS-DWith XIFAXAN
Featuring Mark Pimentel, MD, Darren Brenner, MD, and Joscelyn Greaves, NP
Learn how XIFAXAN may be able to help your adult patients with IBS-D and how to appropriately set expectations prior to treatment.
Diagnostic Recommendations for IBS-D and Treatment Using Rifaximin: Real-World Perspectives
Darren Brenner, MD, speaks about the efficacy and safety of XIFAXAN shown in clinical trials. Review key data supporting the use of XIFAXAN for your adult patients with IBS-D.
For Your Patients
Encourages patients to have a discussion with you about the symptoms they experience and if treatment with XIFAXAN may be an option. Have your patients complete the quick discussion questions to aid in symptom-based diagnosis.
Informational brochure for patients that provides an overview of IBS-D and treatment with XIFAXAN, including how XIFAXAN works, how to take XIFAXAN, efficacy, safety, and most common side effects. Provide this brochure to patients to help them understand treatment with XIFAXAN.
XIFAXAN Savings Card
Most eligible* patients with commercial insurance and coverage for XIFAXAN may pay as little as $0 for their XIFAXAN prescription. Maximum benefits and other restrictions apply.
Core information on XIFAXAN for the treatment of IBS-D in adults. Provides an overview of symptom-based diagnosis of IBS-D, pathophysiology, and efficacy and safety data for XIFAXAN, as well as information on insurance coverage.
Review the recommended XIFAXAN dosing for adults with IBS-D.
Video
7 mins
Ensure XIFAXAN Prescriptions Are Written Correctly
Watch as Clinical Pharmacy Specialist Ralph Riello, PharmD, discusses best practices to help with XIFAXAN prior authorization.
Step-by-step guide for completing prior authorization (PA) requirements for patients prescribed XIFAXAN, including common reasons for PA denials and guidance for Letters of Medical Necessity when needed. Download for guidance on PA requests, as well as information on electronic submissions with CoverMyMeds.
A tier exemption request to reduce the cost-share of a medication. Follows submission of a prior authorization or utilization management request.
A standard form for a patient-specific letter of medical necessity to explain your clinical decision-making in choosing a therapy.
*Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full cash-paying patients. Maximum benefits and other restrictions apply. Visit https://xifaxan.copaysavingsprogram.com/ or call 1-866-XIFAXAN for full eligibility criteria, terms and conditions.
PEER PERSPECTIVES
In this video series, Kathryn Jack, APRN, is “on call” to share her practical perspectives on common questions APPs have about identifying and caring for patients with IBS-D.
Video
3 mins
Episode 1: Addressing the Stigma of Symptoms
Patients are often reluctant to discuss gastrointestinal symptoms with their clinicians. Hear Kathryn’s approach to encouraging an open dialogue with patients and how she helps reduce the stigma associated with IBS-D symptoms.
Diagnosis of IBS-D
Video
11 mins
My Approach: Making a Positive IBS-D Diagnosis
A Practical Overview Featuring Jaime Ackerman, PA-C
Watch your peer demonstrate how she uses a guideline-based approach and clinical criteria to make a positive diagnosis of IBS-D.
Informational guide for diagnosing IBS-D, including clinical criteria and suggestions for conversation starters you can use with your patients.
Ten years since its last revision, Rome V provides updated clinical guidance and diagnostic criteria for IBS—see what’s changed and learn how you can incorporate a positive, symptom-based diagnostic approach into your practice.
Understanding IBS-D
Video
19 mins
Potential Causes of Your Adult Patients’ IBS-D Symptoms
Hosted by Christina J. Hanson, FNP
Featuring Amy Kassebaum, PA-C, MMS, RD
Learn about factors that are thought to contribute to IBS-D symptoms.
Video
3 mins
Bacterial Imbalance and IBS-D Symptoms
Video
6 mins
How XIFAXAN® (rifaximin) Is Thought to Work
Video
3 mins
Expert Discussion: The Role of Dysbiosis in the Pathophysiology of IBS-D
Watch Christopher Chang, MD, explain how microbial imbalances in the gut are thought to be linked to IBS-D symptoms.
Video
13 mins
Expert Discussion: Role Gut Microbiota May Play in the Etiology of IBS-D
Discussion from experts Mark Pimentel, MD, and Darren Brenner, MD, on the role of gut microbiota in human health and how dysbiosis may lead to symptoms of IBS-D.
Video
6 mins
Expert Discussion: Pathophysiology of IBS-D and Mechanism of Action of XIFAXAN
Discussion from expert Mark Pimentel, MD, on the complex pathophysiology of IBS-D and the mechanism of action of XIFAXAN.
PEER PERSPECTIVES
In this video series, Kathryn Jack, APRN, is “on call” to share her practical perspectives on common questions APPs have about identifying and caring for patients with IBS-D.
Video
3 mins
Episode 2: Efficient Care Delivery
Patients with IBS-D often delay seeking professional care and may learn to live with their symptoms. See Kathryn’s approach to making a prompt diagnosis and expediting management to meet her patients’ treatment goals.
Video
3 mins
Episode 3: Guideline-Directed Care
Management of IBS-D warrants careful consideration to accommodate patient preferences and help address multiple symptoms. Learn how Kathryn determines the best treatment pathway for her patients among the various management options available for IBS-D.
Clinical Practice
Watch fellow clinicians discuss clinical insights in the management of adult patients with IBS-D.
Video
10 mins
My Approach: Expediting IBS-D Management
A Practical Overview Featuring Tedra Gray, NP
See how your peer creates an open dialogue with a hypothetical patient, and gain insights into managing multiple symptoms of IBS-D. Discover why Tedra chooses XIFAXAN for her adult patients with IBS-D.
Video
16 mins
Expert Discussion: Treating IBS-D as a Multi-Symptom Condition
Watch Darren Brenner, MD, explain the importance of recognizing the multiple symptoms of IBS-D and how XIFAXAN may help address these symptoms.
Video
10 mins
Expert Discussion: Managing IBS-D Symptoms
Featuring Mark Pimentel, MD, Darren Brenner, MD, and Joscelyn Greaves, NP
Learn about nonpharmacologic and pharmacologic interventions to help manage IBS-D and the challenges faced by patients living with IBS-D.
Video
23 mins
Managing Your Adult Patients’ IBS-D Symptoms
Hosted by Christina J. Hanson, FNP
Featuring Kim Orleck, PA-C
Recognize the recurring symptoms of IBS-D, and learn how treatment with XIFAXAN may help provide relief for your appropriate patients.1,2
Video
3 mins
Connecting With IBS-D Patients and Defining Success
Video
8 mins
Managing IBS-D With XIFAXAN® (rifaximin)
EXPERT INSIGHTS
Video
7 mins
Expert Review: Efficacy and Safety of XIFAXAN
Darren Brenner, MD speaks about the efficacy and safety of XIFAXAN shown in clinical trials. Review key data supporting the use of XIFAXAN for your adult patients with IBS-D.
Video
4 mins
Expert Discussion: ACG Recommendation for XIFAXAN
Watch Brooks Cash, MD, discuss the inclusion of XIFAXAN as a treatment for adults with IBS-D in the American College of Gastroenterology’s 2020 Clinical Guideline on Managing IBS-D.
Video
16 mins
Expert Discussion: Treating IBS-DWith XIFAXAN
Featuring Mark Pimentel, MD, Darren Brenner, MD, and Joscelyn Greaves, NP
Learn how XIFAXAN may be able to help your adult patients with IBS-D and how to appropriately set expectations prior to treatment.
Diagnostic Recommendations for IBS-D and Treatment Using Rifaximin: Real-World Perspectives
Darren Brenner, MD, speaks about the efficacy and safety of XIFAXAN shown in clinical trials. Review key data supporting the use of XIFAXAN for your adult patients with IBS-D.
For Your Patients
Encourages patients to have a discussion with you about the symptoms they experience and if treatment with XIFAXAN may be an option. Have your patients complete the quick discussion questions to aid in symptom-based diagnosis.
Informational brochure for patients that provides an overview of IBS-D and treatment with XIFAXAN, including how XIFAXAN works, how to take XIFAXAN, efficacy, safety, and most common side effects. Provide this brochure to patients to help them understand treatment with XIFAXAN.
XIFAXAN Savings Card
Most eligible* patients with commercial insurance and coverage for XIFAXAN may pay as little as $0 for their XIFAXAN prescription. Maximum benefits and other restrictions apply.
Core information on XIFAXAN for the treatment of IBS-D in adults. Provides an overview of symptom-based diagnosis of IBS-D, pathophysiology, and efficacy and safety data for XIFAXAN, as well as information on insurance coverage.
Review the recommended XIFAXAN dosing for adults with IBS-D.
Video
7 mins
Ensure XIFAXAN Prescriptions Are Written Correctly
Watch as Clinical Pharmacy Specialist Ralph Riello, PharmD, discusses best practices to help with XIFAXAN prior authorization.
Step-by-step guide for completing prior authorization (PA) requirements for patients prescribed XIFAXAN, including common reasons for PA denials and guidance for Letters of Medical Necessity when needed. Download for guidance on PA requests, as well as information on electronic submissions with CoverMyMeds.
A tier exemption request to reduce the cost-share of a medication. Follows submission of a prior authorization or utilization management request.
A standard form for a patient-specific letter of medical necessity to explain your clinical decision-making in choosing a therapy.
*Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program (each a Government Program), or where prohibited by law. Patient must be enrolled in, and must seek reimbursement from or submit a claim for reimbursement to, a commercial insurance plan. Offer excludes full cash-paying patients. Maximum benefits and other restrictions apply. Visit https://xifaxan.copaysavingsprogram.com/ or call 1-866-XIFAXAN for full eligibility criteria, terms and conditions.
INDICATIONS
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
IMPORTANT SAFETY INFORMATION
- XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
- Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
References: 1. XIFAXAN (rifaximin) tablets [package insert]. Bridgewater, NJ: Salix Pharmaceuticals. 2. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393-1407.